MENS Jyong Bio: Enterprise Value to EBITDA Ratio
Low transaction volumes at Jyong Biotech Ltd (MENS) limit operating leverage, keeping margins at a starting plateau. However, innovative plant-based urology formulas are filling the niche between traditional medicine and the FDA. The business valuation based on EV/EBITDA demonstrates resilience, where 0.00 represents the latest level. Thermal containers ensure supply reliability, although they increase bio-logistics costs for extracts.
Comprehensive metric breakdowns and analytics for jyongbio.com (MENS)
- market price and analyst price targets:
- company stock capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
- financial results and valuation multiples details:
MENS - Company Profit|Projected Future Earnings Jyong Biotech Ltd|MENS - Market Cap to Net Income Ratio|Projected Price to Earnings Jyong Biotech Ltd|MENS - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Jyong Bio|MENS - Profit before payment of interest, taxes and amortization|Net earnings per share (EPS TTM) Jyong Biotech|MENS - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months jyongbio.com|MENS - Earnings per share growth rate in current year|Expected earnings per share growth for next year Jyong Biotech Ltd
- company sales and revenue statistics:
General company analysis:Jyong Biotech Corp (MENS)
As Jyong Biotech Ltd (MENS) focuses on the commercialization of innovative urological drugs, the issuer's revenue is currently in its early stages. The current value of 0.00 reflects the ratio of total enterprise value to operating profit, allowing for an assessment of the company's ability to service its obligations through cash flow, which is clearly evidenced by the historical EV/EBITDA value.
Competitor analysis
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Haleon Group HLN|Kenvue Health (KVUE) - Company Value to EBITDA|VRNA: Enterprise Value to EBITDA Ratio|ligand.com - Enterprise Value to Operating Income Before Depreciation Ratio|AMRX: EV/EBITDA Multiple|Perrigo Company PLC - Business Value to Operating Income Before Depreciation|ALVO (Alvotech Corp) - EV/EBITDA Multiple|Company Value to EBITDA Liquidia Inc. LQDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Galapagos NV (GLPG)|ANIP (anipharmaceuticals.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MannKind MNKD|Enterprise Value to Operating Income Before Depreciation Ratio AMPH (Amphastar Pharmaceuticals Inc)|PCRX: Enterprise Value to EBITDA Ratio|Company Value to EBITDA ARS Corp|Theravance Biopharma (TBPH) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA aquestive.com (AQST)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization scPharmaceuticals, Inc.|Enterprise Value to Operating Income Before Depreciation TECX (Tectonic)|EV/EBITDA Multiple TNXP|sxtchina.com (SXTC) - Enterprise Value to EBITDA Multiple|Eupraxia Pharmaceuticals Inc. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation BHST|eXoZymes - EV/EBITDA Multiple|ORMP: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ENTX: EV/EBITDA Multiple|HYFT - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ABVC BioPharma|Company Value to EBITDA cumberlandpharma.com CPIX|Enterprise Value to EBITDA Ratio QNTM (Quantum BioPharma)|Enterprise Value to Operating Income Before Depreciation Ratio FGEN|EV/EBITDA Multiple TELO (Telomir Pharma)|Rani Therapeutics Holdings (RANI) - Company Value to EBITDA|Synergy CHC Corporation - EV/EBITDA Multiple|Rallybio Corporation (RLYB) - Enterprise Value to EBITDA Ratio|LEXX: EV/EBITDA Multiple|Pulmatrix Inc - Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio PTHL|APM: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Lyra Therapeutics, Inc. (LYRA)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization IBO (impactbiomedinc.com)|TNF Pharmaceuticals, Inc. - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio YCBD (cbdMD Inc.)|PainReform Limited - EV/EBITDA Multiple|CYTO (Altamira Therapeutics) - Enterprise Value to Operating Income Before Depreciation|Lipella Pharmaceuticals (LIPO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio optinose.com|PIRS (Pieris Pharmaceuticals, Inc.) - EV/EBITDA Multiple|Company Value to EBITDA Procaps Group PROC|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Petros (PTPI)|Qilian International Corp - Enterprise Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Acelyrin, Inc. SLRN|Total Company Value to Operating Income Before Depreciation Ratio tffpharma.com (TFFP)
